Chlorambucil/obinutuzumab

Chlorambucil/obinutuzumab Reactions 1704, p93 - 2 Jun 2018 Infusion related reaction and cytopenia: 2 case reports In a retrospective review of nine patients, two elderly patients [exact ages and sexes not stated] were described, out of whom, one patient developed infusion related reaction and the other patient developed cytopenia during treatment with obinutuzumab and chlorambucil for chronic lymphatic leukaemia [dosages and outcome not stated]. Case 1: The patient, who had an untreated chronic lymphatic leukaemia, started receiving treatment with an infusion of obinutuzumab and chlorambucil. At the time of treatment initiation, the patient had lymphocyte count in excess of 100. With the first infusion of obinutuzumab and chlorambucil, the patient developed grade III infusion related reaction. Subsequently, infusion related reaction resolved and did not recur during further treatment. Case 2: The patient, who had an untreated chronic lymphatic leukaemia, started receiving treatment with an infusion of obinutuzumab and chlorambucil. Subsequently, the patient developed treatment-related grade III/IV cytopenias after every cycle. Therefore, treatment with obinutuzumab and chlorambucil was discontinued after three cycles. Author comment: "All patients initiated on Obinutuzumab and Chlorambucil were included." "Objectives: To assess safety including infusion related reactions and cytopenias and response to treatment." "Out of 9 patients, 7 patients had grade 1–2 infusion reactions, 1 had grade 3 reaction . . . 1 patient had to discontinue after 3 cycles for grade 3/4 cytopenias after every cycle." Owen S, et al. Single hospital retrospective review of obinutuzumab and chlorambucil combination therapy in patients with untreated chronic lymphatic leukaemia in a district general hospital (DGH). British Journal of Haematology 181 (Suppl. 1): 182 abstr. BSH18-EP-048, Apr 2018. Available from: URL: http:// doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323318 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Chlorambucil/obinutuzumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/chlorambucil-obinutuzumab-NCUM1XLc7M
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46736-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p93 - 2 Jun 2018 Infusion related reaction and cytopenia: 2 case reports In a retrospective review of nine patients, two elderly patients [exact ages and sexes not stated] were described, out of whom, one patient developed infusion related reaction and the other patient developed cytopenia during treatment with obinutuzumab and chlorambucil for chronic lymphatic leukaemia [dosages and outcome not stated]. Case 1: The patient, who had an untreated chronic lymphatic leukaemia, started receiving treatment with an infusion of obinutuzumab and chlorambucil. At the time of treatment initiation, the patient had lymphocyte count in excess of 100. With the first infusion of obinutuzumab and chlorambucil, the patient developed grade III infusion related reaction. Subsequently, infusion related reaction resolved and did not recur during further treatment. Case 2: The patient, who had an untreated chronic lymphatic leukaemia, started receiving treatment with an infusion of obinutuzumab and chlorambucil. Subsequently, the patient developed treatment-related grade III/IV cytopenias after every cycle. Therefore, treatment with obinutuzumab and chlorambucil was discontinued after three cycles. Author comment: "All patients initiated on Obinutuzumab and Chlorambucil were included." "Objectives: To assess safety including infusion related reactions and cytopenias and response to treatment." "Out of 9 patients, 7 patients had grade 1–2 infusion reactions, 1 had grade 3 reaction . . . 1 patient had to discontinue after 3 cycles for grade 3/4 cytopenias after every cycle." Owen S, et al. Single hospital retrospective review of obinutuzumab and chlorambucil combination therapy in patients with untreated chronic lymphatic leukaemia in a district general hospital (DGH). British Journal of Haematology 181 (Suppl. 1): 182 abstr. BSH18-EP-048, Apr 2018. Available from: URL: http:// doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323318 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off